JOP20240195A1 - أشكال نقية من أتيكابرانت البلوري - Google Patents
أشكال نقية من أتيكابرانت البلوريInfo
- Publication number
- JOP20240195A1 JOP20240195A1 JOJO/P/2024/0195A JOP20240195A JOP20240195A1 JO P20240195 A1 JOP20240195 A1 JO P20240195A1 JO P20240195 A JOP20240195 A JO P20240195A JO P20240195 A1 JOP20240195 A1 JO P20240195A1
- Authority
- JO
- Jordan
- Prior art keywords
- aticabrant
- crystalline
- pure forms
- aticaprant
- solvates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240195A1 true JOP20240195A1 (ar) | 2024-09-05 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0195A JOP20240195A1 (ar) | 2022-03-07 | 2024-09-05 | أشكال نقية من أتيكابرانت البلوري |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (OSRAM) |
| EP (1) | EP4489748A1 (OSRAM) |
| JP (1) | JP2025508071A (OSRAM) |
| KR (1) | KR20240158951A (OSRAM) |
| CN (1) | CN119156210A (OSRAM) |
| AU (1) | AU2023231493A1 (OSRAM) |
| CA (1) | CA3254503A1 (OSRAM) |
| CL (1) | CL2024002643A1 (OSRAM) |
| CO (1) | CO2024012457A2 (OSRAM) |
| IL (1) | IL315411A (OSRAM) |
| JO (1) | JOP20240195A1 (OSRAM) |
| MX (1) | MX2024010978A (OSRAM) |
| PE (1) | PE20242109A1 (OSRAM) |
| TW (1) | TW202345795A (OSRAM) |
| WO (1) | WO2023170547A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| TW202400135A (zh) | 2022-03-07 | 2024-01-01 | 美商健生醫藥公司 | 包含阿替卡普蘭之組成物 |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017484B1 (ru) * | 2008-01-22 | 2012-12-28 | Эли Лилли Энд Компани | Селективный антагонист опиоидных рецепторов каппа |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| KR20240004857A (ko) * | 2021-05-04 | 2024-01-11 | 얀센 파마슈티칼즈, 인코포레이티드 | 우울증 치료를 위한 조성물 및 방법 |
-
2023
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119156210A (zh) | 2024-12-17 |
| US20230348377A1 (en) | 2023-11-02 |
| EP4489748A1 (en) | 2025-01-15 |
| IL315411A (en) | 2024-11-01 |
| JP2025508071A (ja) | 2025-03-21 |
| US20250326714A1 (en) | 2025-10-23 |
| AU2023231493A1 (en) | 2024-10-24 |
| MX2024010978A (es) | 2024-12-06 |
| CA3254503A1 (en) | 2023-09-14 |
| KR20240158951A (ko) | 2024-11-05 |
| PE20242109A1 (es) | 2024-10-28 |
| CO2024012457A2 (es) | 2024-09-30 |
| TW202345795A (zh) | 2023-12-01 |
| WO2023170547A1 (en) | 2023-09-14 |
| CL2024002643A1 (es) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010978A (es) | Formas puras de aticaprant cristalino | |
| MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
| MX2023012245A (es) | Compuestos, composiciones y metodos para el tratamiento del cancer. | |
| PH12023500015A1 (en) | Irak degraders and uses thereof | |
| MX2025015367A (es) | Inhibidores del oncogen del sarcoma de rata de kirsten (kras) | |
| MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
| PH12023500023A1 (en) | Cdk2 degraders and uses thereof | |
| MX2025015277A (es) | Inhibidores de masp-2 y metodos de uso | |
| MX2023014154A (es) | Anticuerpos anti-ccr8. | |
| SA522431538B1 (ar) | طُرق وتركيبات لعلاج تساقط الشعر | |
| CO2024004970A2 (es) | Agentes degradantes de tyk2 y sus usos | |
| JOP20210245A1 (ar) | طرق لعلاج الداء النشواني من النوع خفيف السلسلة | |
| MX2025006853A (es) | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos | |
| MX2020009147A (es) | Moduladores de la expresion de irf4. | |
| MX2024014079A (es) | Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2025006791A (es) | Agente de iarn con nucleótidos modificados | |
| MX2025003568A (es) | Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap) | |
| MX2022007190A (es) | Analogos de cistina diamida para la cistinuria. | |
| BR112021019448A2 (pt) | Métodos para o tratamento de beta-talassemia | |
| MX2023014984A (es) | Anticuerpos anti-csp. | |
| MX2025012761A (es) | Moleculas y metodos de uso de estas | |
| CL2024002103A1 (es) | Métodos para tratar amiloidosis al | |
| MA70825B1 (fr) | Traitement de douleur associée à la sensibilisation centrale |